Search research articles
Contact Us
Filters
Showing results (51-60 of 53) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 53 results.
Lancet (London, England)
|
April 5, 2026
Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial
Emil Nielsen Holck, Niels R Holm, David Hildick-Smith, et al.
Lancet (London, England)
|
December 28, 2019
Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial
Niels R Holm, Timo Mäkikallio, M Mitchell Lindsay, et al.
Lancet (London, England)
|
November 7, 2016
Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial
Timo Mäkikallio, Niels R Holm, Mitchell Lindsay, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 53) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 53 results.
Lancet (London, England)
|
April 5, 2026
Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial
Emil Nielsen Holck, Niels R Holm, David Hildick-Smith, et al.
Lancet (London, England)
|
December 28, 2019
Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial
Niels R Holm, Timo Mäkikallio, M Mitchell Lindsay, et al.
Lancet (London, England)
|
November 7, 2016
Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial
Timo Mäkikallio, Niels R Holm, Mitchell Lindsay, et al.
Page
of 6